- Exchange: EN Amsterdam
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Pharming Group NV
Add to PortfolioPHARM:NA
0.0340 EUR 0.0030 8.11%As of 11:35:00 ET on 05/29/2012.
Snapshot for Pharming Group NV (PHARM)
| Open: | 0.0370 | Day's Range: | 0.0320 - 0.0380 | Volume: | 19,314,449 | Bid: | 0.0330 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 0.0370 | 52wk Range: | 0.0320 - 0.1480 | 1-Yr Rtn: | -76.87% | Ask: | 0.0340 |
Key Statistics for PHARM
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (EUR) (ttm) | -0.0480 |
| Est. EPS (EUR) (12/2012) | -0.0310 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 21.25 |
| Shares Outstanding (M) | 625.08 |
| Enterprise Value (M EUR) (ttm) | 16.98 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 5.1112 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/23/2012 |
More PHARM Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for PHARM
- Operating
- Investing
- Financing (M/EUR)
Company Profile & Key Executives for PHARM
Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.
| Sijmen De VriesChairman-Mgmt Board/CEO | Karl D KeeganCFO/Member Mgmt Board |
| Bruno M L GiannettiChief Operations Officer | Rienk R D PijpstraChief Medical Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page